Catabasis Pharma (CATB) Tops Q4 EPS by 7c, Beats on Revenues

Note: EPS may not be comparable

Catabasis Pharma (NASDAQ: CATB) reported Q4 EPS of ($0.24), $0.07 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $250 thousand versus the consensus estimate of $130 thousand.

For earnings history and earnings-related data on Catabasis Pharma (CATB) click here.

You May Also Be Interested In

• Rent the Runway (RENT) Reports Q2 Loss of $0.38/sh
• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• S&P 500 above 8,000 in 2026 now looks ambitious, Citi says